Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Appointed director
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates"
05/09/2023 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates"
02/28/2023 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates"
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates"
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate Updates Registration-Directed Study Initiated in Non-Small Cell Lung Cancer SAN CARLOS, Calif., Nov 5, 2020 -- Iovance Biotherapeutics, Inc. , a late-stage biotechnology company developing novel T cell-based cancer immunotherapies , today reported third quarter 2020 financial results and provided a corporate update. “Subsequent to meeting with FDA, we have moved the BLA submission date for lifileucel to 2021 in order to reach agreement on the required potency assays to fully define TIL,” said Maria Fardis, PhD, President and CEO of Iovance. “In additional indications, we look forward to starting our registration-directed study in non-small cell lung cancer, and to presenting initial clinical..."
08/06/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
11/04/2019 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results"
08/01/2019 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update"
05/07/2019 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update"
02/27/2019 8-K Quarterly results
11/06/2018 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update"
08/06/2018 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update"
05/10/2018 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update"
03/12/2018 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update"
10/31/2017 8-K Quarterly results
05/01/2017 8-K Form 8-K - Current report
03/07/2017 8-K Form 8-K - Current report
11/04/2016 8-K Quarterly results
Docs: "Lion Biotechnologies Reports Third Quarter 2016 Financial Results and Provides Corporate Update"
08/08/2016 8-K Quarterly results, Appointed a new director
Docs: "Office Lease, effective as of August 1, 2016, between Lion Biotechnologies, Inc. and Hudson Skyway Landing, LLC",
"Lion Biotechnologies Announces Second Quarter 2016 Financial Results"
05/09/2016 8-K Form 8-K - Current report
03/10/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "Lion Biotechnologies Announces Third Quarter 2015 Financial Results"
08/10/2015 8-K Quarterly results
Docs: "Lion Biotechnologies Announces Second Quarter 2015 Financial Results – Lion Biotechnologies, Inc. , a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes , today reported financial results for the second quarter and six months ended June 30, 2015. For the second quarter and six months ended June 30, 2015, the Company reported operating expenses of $2.4 million and $4.9 million, respectively, compared to $1.6 million and $3.1 million respectively for the comparable 2014 periods. Research and development expenses totaled $4.1 million and $6.8 million, respectively, for the three and six months ended June 30, 2015, compared to $0.5 million and $1.2 million, respectively, for the same periods in 2014. During the six months ended June 30..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy